<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966832</url>
  </required_header>
  <id_info>
    <org_study_id>XW10508-101</org_study_id>
    <nct_id>NCT04966832</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of XW10508 Immediate and Modified Release Formulations in Healthy Adults</brief_title>
  <official_title>A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of XW10508 Immediate and Modified Release Formulations in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XWPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XWPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of&#xD;
      XW10508 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human single and multiple ascending oral dose pharmacokinetic and safety&#xD;
      study where participants will receive either XW10508 or placebo. Both immediate release and&#xD;
      modified release formulations will be assessed. Timed blood samples will be collected to&#xD;
      assess the pharmacokinetics after the study drug is ingested by the participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In this double-blind study, participants will be randomized to XW10508 or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, severity, and causality of adverse events (AEs)</measure>
    <time_frame>Up to 12 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Cmin)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) from 0 to time of last quantifiable concentration</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time 0 extrapolated to infinity (AUC0-inf)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC over the dosing interval (AUCtau)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t1/2)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax and AUC ratios of metabolites to XW10172</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>XW10508</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XW10508 capsules or tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules or tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XW10508</intervention_name>
    <description>XW10508 capsules or tablets</description>
    <arm_group_label>XW10508</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules or tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female participants who are 18 to 55 years of age, inclusive.&#xD;
&#xD;
          -  Participant is willing and able to provide signed and dated written informed consent&#xD;
             to participate prior to admission to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant (in the opinion of the investigator)&#xD;
             gastrointestinal, hepatic, renal, respiratory (e.g., asthma, COPD), cardiovascular&#xD;
             (e.g., hypertension), metabolic, psychiatric, neurological, immunological, or&#xD;
             endocrine disorders, or allergic disease including drug allergies, including immediate&#xD;
             type hypersensitivity to components of the study drug. A history of childhood asthma&#xD;
             that has resolved is acceptable.&#xD;
&#xD;
          -  Use of tobacco- or nicotine-containing products (e.g., cigarettes, cigars, chewing&#xD;
             tobacco, snuff, patches, vaping device, etc.) within 3 months prior to Day -1 and/or&#xD;
             positive urine cotinine test at Screening or Day -1.&#xD;
&#xD;
          -  Participant who, for any reason, is deemed by the investigator to be inappropriate for&#xD;
             this study; or has any condition which would confound or interfere with the evaluation&#xD;
             of the safety, tolerability, pharmacokinetics or pharmacodynamics of the&#xD;
             investigational drug; or is unable to comply with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M Canafax, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>XWPharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Zib</last_name>
    <phone>650-885-9682</phone>
    <email>Beth.Zib@XWPharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Lee</last_name>
      <phone>0570887900</phone>
      <email>susan.lee@cmax.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

